Ailsa J. Frew

1.5k total citations · 1 hit paper
7 papers, 1.3k citations indexed

About

Ailsa J. Frew is a scholar working on Molecular Biology, Physiology and Immunology. According to data from OpenAlex, Ailsa J. Frew has authored 7 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 2 papers in Physiology and 2 papers in Immunology. Recurrent topics in Ailsa J. Frew's work include Histone Deacetylase Inhibitors Research (4 papers), Protein Degradation and Inhibitors (3 papers) and Cell death mechanisms and regulation (2 papers). Ailsa J. Frew is often cited by papers focused on Histone Deacetylase Inhibitors Research (4 papers), Protein Degradation and Inhibitors (3 papers) and Cell death mechanisms and regulation (2 papers). Ailsa J. Frew collaborates with scholars based in Australia, United States and Japan. Ailsa J. Frew's co-authors include Ricky W. Johnstone, Mark J. Smyth, Jessica E. Bolden, Ralph K. Lindemann, Clare L. Scott, Anthony E. Dear, Leonie A. Cluse, Leigh Ellis, Scott W. Lowe and Marc Pellegrini and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature reviews. Cancer and The Journal of Immunology.

In The Last Decade

Ailsa J. Frew

7 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The TRAIL apoptotic pathway in cancer onset, progression and therapy

2008 712 citations Ricky W. Johnstone, Ailsa J. Frew et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Ailsa J. Frew

Since Specialization

Citations

This map shows the geographic impact of Ailsa J. Frew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ailsa J. Frew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ailsa J. Frew more than expected).

Fields of papers citing papers by Ailsa J. Frew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ailsa J. Frew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ailsa J. Frew. The network helps show where Ailsa J. Frew may publish in the future.

Co-authorship network of co-authors of Ailsa J. Frew

This figure shows the co-authorship network connecting the top 25 collaborators of Ailsa J. Frew. A scholar is included among the top collaborators of Ailsa J. Frew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ailsa J. Frew. Ailsa J. Frew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Antitumor activities and on‐target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat 2010 ·International Journal of Cancer ·Ben P. Martin, Ailsa J. Frew, Michael Bots, Stephen B. Fox, Fenella Long, Kazuyoshi Takeda, Hideo Yagita∥, Peter Atadja, Mark J. Smyth, Ricky W. Johnstone	12
2	Enhancing the apoptotic and therapeutic effects of HDAC inhibitors 2009 ·Cancer Letters ·Ailsa J. Frew, Ricky W. Johnstone, Jessica E. Bolden	195
3	The TRAIL apoptotic pathway in cancer onset, progression and therapy breakdown → 2008 ·Nature reviews. Cancer ·Ricky W. Johnstone, Ailsa J. Frew, Mark J. Smyth	712
4	Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist 2008 ·Proceedings of the National Academy of Sciences ·Ailsa J. Frew, Ralph K. Lindemann, Ben P. Martin, Christopher J. Clarke, Janelle Sharkey, (unknown), Kellie-Marie Banks, Nicole M. Haynes, Pradnya Gangatirkar, Kym L. Stanley, Jessica E. Bolden, Kazuyoshi Takeda, Hideo Yagita∥, J. Paul Secrist, Mark J. Smyth, Ricky W. Johnstone	118
5	Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma 2007 ·Proceedings of the National Academy of Sciences ·Ralph K. Lindemann, Andrea Newbold, Kate F. Whitecross, Leonie A. Cluse, Ailsa J. Frew, Leigh Ellis, Steven P. Williams, Adrian P. Wiegmans, Anthony E. Dear, Clare L. Scott, Marc Pellegrini, Andrew H. Wei, Victoria M. Richon, Paul A. Marks, Scott W. Lowe, Mark J. Smyth, Ricky W. Johnstone	166
6	Inhibition of Arginase I Activity by RNA Interference Attenuates IL-13-Induced Airways Hyperresponsiveness 2006 ·The Journal of Immunology ·Ming Yang, Danny Rangasamy, Klaus I. Matthaei, Ailsa J. Frew, (unknown), Suresh Mahalingam, Dianne C. Webb, David J. Tremethick, Philip J. Thompson, Simon P. Hogan, Marc E. Rothenberg, William B. Cowden, Paul S. Foster	79
7	Immunohistology of Human Allergic Late-Phase Skin Reactions 1991 ·Skin Pharmacology and Physiology ·Ailsa J. Frew, Veronica Varney, Mina Gaga, A.B. Kay	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact